FEATURED EDITORIAL
Induced proximity has evolved into a versatile platform with the potential to change drug discovery, but challenges still remain.
- ASH 2025 Reveals Strategic Implications For AML Drug Development
- Advances In Endometrial-Targeted Drug Delivery In Women's Health
- Thoughtful Supply Strategy Is No Longer Optional In Drug Development
- Building Inclusivity Into Early-Stage Preclinical Drug Discovery
- Rethinking Disease Modification Through Targeted Immunotherapy
- New Approach Methods In Practice: Where Are We Today?
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
FEATURED APPLICATION CONTENT
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
Discover how mixed-mode chromatography enables high-yield purification of single-domain antibodies under mild conditions and why these approaches outperform traditional resins.
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
-
Decoding immune cell interactions reveals critical insights for cancer therapy. Advanced imaging and spectral analysis enable precise identification of synapses, accelerating immuno-oncology research.
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- Annual Reflections And Predictions From The Editors' Roundtable
- The Unlikely Weapon Against Fentanyl: Your Immune System
- 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026
FEATURED NEWS HEADLINES
- Panome Bio Introduces MassID™ A Major Advance In Untargeted Metabolomics Data Analysis For Biomarker Discovery And Drug Development
- FDA Accepts Viatris Supplemental New Drug Application For MR-141 (Phentolamine Ophthalmic Solution 0.75%) For The Treatment Of Presbyopia
- MindRank Announces First Patient Dosed In Phase III Trial Of AI-Designed Oral GLP-1 Receptor Agonist MDR-001
- Helsinn Healthcare & InVirtuoLabs Sign A Strategic Collaboration In AI-Driven Drug Discovery
- IQVIA Signs Agreement To Acquire Drug Discovery Assets From Charles River Laboratories, Expanding End-To-End Drug Discovery Capabilities
- Lupin Announces The Approval And Launch Of Brivaracetam Oral Solution In The United States
- Draper And Partners Awarded ARPA-H Funding To Develop New In Silico Models Of Human Physiology For Drug Development
- Angelini Pharma And Quiver Bioscience Announce Strategic Research Collaboration And Licensing Agreement To Discover And Advance Novel Therapeutics For Genetic Epilepsies
- FDA Accepts New Drug Application For Genentech's Giredestrant In ESR1-Mutated, ER-Positive Advanced Breast Cancer
- Sygnature Discovery Unveils Strategic Rebrand To Cement Status As A Global Drug Discovery Partner
ARCHIVED NEWSLETTER
- 02.24.26 -- Small Molecule Enzyme Mimetics In Age-Related Neurodegeneration
- 02.17.26 -- Avoiding Protein Purification Artifacts That Still Undermine Drug Design
- 02.10.26 -- Designing Drugs For Women: Closing The Therapeutic Gap
- 02.03.26 -- CROs In Early Drug Discovery, Part 3: Budgets, Timelines, And Avoiding Pitfalls
- 01.27.26 -- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery